BioInvent International AB announces it has received Investigational New Drug approval for the monoclonal antibody BI-1910, which will now become its second anti-tumor necrosis factor receptor 2 program to enter clinical development.
BioInvent International AB announces it has received Investigational New Drug approval for the monoclonal antibody BI-1910, which will now become its second anti-tumor necrosis factor receptor 2 program to enter clinical development.